Publications

Found 24 results
Author Title Type [ Year(Asc)]
Filters: First Letter Of Last Name is B  [Clear All Filters]
2019
Fernandez EM, Eng K, Beg S, Beltran H, Faltas BM, Mosquera JMiguel, Nanus DM, Pisapia DJ, Rao RA, Robinson BD et al..  2019.  Cancer-Specific Thresholds Adjust for Whole Exome Sequencing-based Tumor Mutational Burden Distribution.. JCO Precis Oncol. 3
Fernandez EM, Eng K, Beg S, Beltran H, Faltas BM, Mosquera JMiguel, Nanus DM, Pisapia DJ, Rao RA, Robinson BD et al..  2019.  Cancer-Specific Thresholds Adjust for Whole Exome Sequencing-based Tumor Mutational Burden Distribution.. JCO Precis Oncol. 3
Schwartz GW, Manning B, Zhou Y, Velu P, Bigdeli A, Astles R, Lehman AW, Morrissette JJD, Perl AE, Li M et al..  2019.  Classes of ITD Predict Outcomes in AML Patients Treated with FLT3 Inhibitors.. Clin Cancer Res. 25(2):573-583.
Kluk MJ, Bagg A.  2019.  Expedited Analysis and Reporting of Multiple Mutations that Modify Medical Management of Myeloid Malignancies: It's About (Turnaround) Time!. J Mol Diagn. 21(1):13-15.
Sailer V, Eng KWa, Zhang T, Bareja R, Pisapia DJ, Sigaras A, Bhinder B, Romanel A, Wilkes D, Sticca E et al..  2019.  Integrative Molecular Analysis of Patients With Advanced and Metastatic Cancer.. JCO Precis Oncol. 3
Sailer V, Eng KWa, Zhang T, Bareja R, Pisapia DJ, Sigaras A, Bhinder B, Romanel A, Wilkes D, Sticca E et al..  2019.  Integrative Molecular Analysis of Patients With Advanced and Metastatic Cancer.. JCO Precis Oncol. 3
Sailer V, Eng KWa, Zhang T, Bareja R, Pisapia DJ, Sigaras A, Bhinder B, Romanel A, Wilkes D, Sticca E et al..  2019.  Integrative Molecular Analysis of Patients With Advanced and Metastatic Cancer.. JCO Precis Oncol. 3
Sailer V, Eng KWa, Zhang T, Bareja R, Pisapia DJ, Sigaras A, Bhinder B, Romanel A, Wilkes D, Sticca E et al..  2019.  Integrative Molecular Analysis of Patients With Advanced and Metastatic Cancer.. JCO Precis Oncol. 3
Sailer V, Eng KWa, Zhang T, Bareja R, Pisapia DJ, Sigaras A, Bhinder B, Romanel A, Wilkes D, Sticca E et al..  2019.  Integrative Molecular Analysis of Patients With Advanced and Metastatic Cancer.. JCO Precis Oncol. 3
Sailer V, Eng KWa, Zhang T, Bareja R, Pisapia DJ, Sigaras A, Bhinder B, Romanel A, Wilkes D, Sticca E et al..  2019.  Integrative Molecular Analysis of Patients With Advanced and Metastatic Cancer.. JCO Precis Oncol. 3
Velu PD, Perl AE, Luger SM, Bagg A, Morrissette JJD.  2019.  Longitudinal targeted next-generation sequencing in a patient with acute myeloid leukaemia.. Br J Haematol. 186(6):801.
Baum JE, Sung K-J, Tran H, Song W, Ginter PS.  2019.  Mammary Epithelial-Myoepithelial Carcinoma: Report of a Case With HRAS and PIK3CA Mutations by Next-Generation Sequencing.. Int J Surg Pathol. 27(4):441-445.
Xing D, Liu Y, Park HJin, Baek I, Tran H, Cheang G, Novo J, Dillon J, Matoso A, Farmer E et al..  2019.  Recurrent genetic alterations and biomarker expression in primary and metastatic squamous cell carcinomas of the vulva.. Hum Pathol. 92:67-80.
Nam AS, Kim K-T, Chaligne R, Izzo F, Ang C, Taylor J, Myers RM, Abu-Zeinah G, Brand R, Omans ND et al..  2019.  Somatic mutations and cell identity linked by Genotyping of Transcriptomes.. Nature. 571(7765):355-360.
2015
Cheng DT, Mitchell TN, Zehir A, Shah RH, Benayed R, Syed A, Chandramohan R, Liu ZYu, Won HH, Scott SN et al..  2015.  Memorial Sloan Kettering-Integrated Mutation Profiling of Actionable Cancer Targets (MSK-IMPACT): A Hybridization Capture-Based Next-Generation Sequencing Clinical Assay for Solid Tumor Molecular Oncology.. J Mol Diagn. 17(3):251-64.
Cheng DT, Mitchell TN, Zehir A, Shah RH, Benayed R, Syed A, Chandramohan R, Liu ZYu, Won HH, Scott SN et al..  2015.  Memorial Sloan Kettering-Integrated Mutation Profiling of Actionable Cancer Targets (MSK-IMPACT): A Hybridization Capture-Based Next-Generation Sequencing Clinical Assay for Solid Tumor Molecular Oncology.. J Mol Diagn. 17(3):251-64.
Cheng DT, Mitchell TN, Zehir A, Shah RH, Benayed R, Syed A, Chandramohan R, Liu ZYu, Won HH, Scott SN et al..  2015.  Memorial Sloan Kettering-Integrated Mutation Profiling of Actionable Cancer Targets (MSK-IMPACT): A Hybridization Capture-Based Next-Generation Sequencing Clinical Assay for Solid Tumor Molecular Oncology.. J Mol Diagn. 17(3):251-64.
Cheng DT, Mitchell TN, Zehir A, Shah RH, Benayed R, Syed A, Chandramohan R, Liu ZYu, Won HH, Scott SN et al..  2015.  Memorial Sloan Kettering-Integrated Mutation Profiling of Actionable Cancer Targets (MSK-IMPACT): A Hybridization Capture-Based Next-Generation Sequencing Clinical Assay for Solid Tumor Molecular Oncology.. J Mol Diagn. 17(3):251-64.
Kluk MJ, Abo RP, Brown RD, Kuo FC, Dal Cin P, Pozdnyakova O, Morgan EA, Lindeman NI, DeAngelo DJ, Aster JC.  2015.  Myeloid neoplasm demonstrating a STAT5B-RARA rearrangement and genetic alterations associated with all-trans retinoic acid resistance identified by a custom next-generation sequencing assay.. Cold Spring Harb Mol Case Stud. 1(1):a000307.